AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05767034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Study NCT05767034 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to secukinumab
Description: Taken subcutaneously every 4 weeks until Week 48 in combination with a 24-week prednisone taper regimen
Study NCT06348329 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth Preparation Training
Description: Birth Preparation Training is planned to include a 4-week program by an internationally certified instructor.
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2102-1
Description: Take once daily for 2 weeks orally
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP2104-1
Description: Placebo drug. Take once daily for 2 weeks orally
Study NCT06232564 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
Description: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy
Study NCT06423820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron lozenge
Description: Pediatric patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.
Study NCT05744687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPH4336 Tablets 400mg
Description: SPH4336 Tablets ：Orally, 400mg once a day; 28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle
Study NCT05744687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SPH4336 Tablets Placebo
Description: SPH4336 Tablets Placebo：Orally,28 days/cycle~Letrozole tablets ：Orally, 2.5mg once a day; 28 days/cycle
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0901
Description: Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab+ paclitaxel
Description: Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)
Study NCT06346392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)
Study NCT06018064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prone Positioner
Description: An innovative device to allow for infants to be supported while in the prone position
Study NCT05621291 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NGS testing
Description: antigen immunophenotype agnostic approach for disease detection using blood and bone marrow samples
Study NCT06348316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Half swaddle
Description: Half swaddle: HS applied to a newborn baby makes the baby feel completely safe, as if in the womb. After laying the soft fabric or baby blanket, it was placed in the supine position. Half swaddling was done so as not to restrict the baby's arm and leg movements. HS was performed 15 minutes before each sleep during the day until the 3rd month.
Study NCT06348316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Description: The application was applied twice a day and for 60 minutes every day for 6 months in a row. During KC, the mother placed her baby between two breasts, and the baby's breast was placed on the mother's breast in an upright position. During the application of KC, a quiet, calm, and the suitable environment was created so that comfort of the baby and mother would not be disturbed. The mother and baby are covered with a blanket. The ambient temperature was 26 centigrade degrees during the kangaroo care. In the continuation of the KB application, the mother was asked to breastfeed her baby. In order to prevent the risk of aspiration of the baby after breastfeeding, the baby was placed in the left lateral position so that the mother and the baby could lie down together. The researcher observed the application steps of the mother's KC, and the deficiencies, if any, were corrected by discussing with the mother during/after the application.
Study NCT05712694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI PEG20
Description: Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Study NCT05450601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP2102-2
Description: Take once daily for 6 weeks orally
Study NCT05220319 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: 100 ml NaCl0,9% as an IV injection at the induction of anaesthesia but before surgery. If CPB is required an additional 100ml will be given.
Study NCT05305118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSCS Mapping
Description: Prior to TSCS Intervention, participants will undergo TSCS Mapping.~Electrode location, pulse frequency will be maintained while the stimulation intensity is ramped from 10 to 200 mA. Brachial blood pressures and symptoms will be monitored and recorded at each ramping interval and will continuously monitor and record beat-to-beat heart rate and blood pressures to determine the optimal site and frequency for further TSCS intervention~TSCS electrodes will be placed at two vertebral levels in the and back and pulse frequency will be set at 30 to 240 Hz to determine the optimal site and frequency for further TSCS intervention.
Study NCT05305118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulation
Description: TSCS will be used as an adjunct intervention to promote blood pressure stability in conjunction with daily physical and occupational therapy in the inpatient rehabilitation gym. Stimulation will be added to therapy 3-5 times per week as needed for the duration of inpatient hospitalization following SCI.~TSCS stimulation will be delivered using Digitimer DS7A, DS8R stimulators and Chattanooga Continuum (DS7A has FDA 510(k) clearance #K051357; Chattanooga Continuum is a Class 2 device).
Study NCT05289817 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Vagus Nerve Stimulation (t-VNS)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: cymba conchae at right ear (vagus branch nerve area); a clip electrode will be applied with its cathode on anterior cymba conchae, the anode placed behind.~Amplitude: from 2 times the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes
Study NCT05289817 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Sympathetic Ganglion Electrical Stimulation (t-SES)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 5 Hz Number of channels: two Location and electrodes: cervicothoracic area (stellate ganglion region); first channel: new 5 cm x 5 cm self-adhesive electrodes will be applied at 1-1.5 cm both sides of the vertebral spinous processes, approximately from C7 to T4, upper cathode on the left side of C7 and lower cathode on the right side.~Amplitude: 2 mA above the muscle contraction threshold (individualized) at a comfortable, non-painful amplitude and to a maximum of 25 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of muscle contraction On-Off times: no trains, continuously delivered Duration: 20 minutes
Study NCT05289817 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcutaneous vagus nerve stimulation (Sham t-VNS)
Description: Type of device and current: portable machine, low frequency current, constant current Type of wave: square biphasic pulses Pulse duration: 350 microseconds Frequency: 10 Hz Number of channels: one Location and electrodes: scapha at right ear (non vagus innervated region); a clip electrode will be applied with its cathode on anterior scapha, the anode placed behind.~Amplitude: from 2 times above the perception threshold (individualized) at a comfortable, non-painful amplitude, and to a maximum of 9 mA. It will be increased, if necessary, each 5 minutes in order to maintain the same level of tingling sensation On-Off times: trains of 30 s on, 5 s rump up, 1 s rump down, 24 s off Duration: 20 minutes
Study NCT06398730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEH200520 Injection and GEH200521 (18F) Injection
Description: Administration of GEH200520 Injection followed by GEH200521 (18F) Injection
Study NCT05712694 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment for advanced or metastatic uterine/non-uterine leiomyosarcoma (LMS)
Study NCT06442787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: conventional splints
Description: only intermediate and final splint will be used during the surgery
Study NCT06442787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting guides and positioning guides
Description: patient's specific manufacturing cutting guide and positioning guide related with orthognathic surgery
Study NCT06442787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cutting guides and fixation plates
Description: patient's specific manufacturing cutting guide and fixation plates related with orthognathic surgery
Study NCT05836870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Participants will receive general recommendations to maintain physical activity.
Study NCT05836870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-supervised resistance exercises
Description: Participants will take part in a monitored exercise program.
Study NCT06398730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static - PET/CT scan
Description: Repeat whole body static scan starting 3 minutes after injection followed by a single whole body static scan at 2 to 3 hours after injection and 4 to 5 hours after injection
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avutometinib
Description: Avutometinib: administered orally
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Defactinib: administered orally
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Description: administered intravenously
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: administered intravenously
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: administered orally
Study NCT06072781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: administered orally
Study NCT06431633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: Zimberelimab is a fully human IgG4 monoclonal antibody targeting human PD-1. PD-1 is a type I transmembrane protein that is part of the immunoglobulin gene superfamily and the CD28 family of cell surface receptors. PD-1 is an inhibitory immune checkpoint protein that is expressed on activated B cells, T cells, and myeloid cells, and it plays a key role in limiting the activity of effector T cells.~Zimberelimab is formulated at 30 mg/mL in a buffer solution containing histidine/histidine-HCl buffer solution, sucrose, sodium chloride, and polysorbate 80, at pH 5.5. The investigational product is supplied as a vial contains 120 mg of active Zimberelimab at a concentration of 30mg/mL.~No premedication nor profilaxis is needed before Zimberelimab administration. Zimberelimab doses are administered by IV infusion over 60 minutes, followed by a 30- to 60-minute observation period, on D1 of each 21-day cycle.
Study NCT06431633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: Sacituzumab govitecan (SG) is an ADC composed of the following 3 components:~o The humanized monoclonal antibody hRS7 IgG1κ, which binds to Trop-2, a transmembrane calcium signal transducer that is overexpressed in many epithelial cancers.~o The camptothecin-derived agent SN-38, a topoisomerase I inhibitor. o A hydrolyzable linker, with the company designation as CL2A that links the humanized monoclonal antibody to SN-38.~Sacituzumab govitecan is approved globally for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and HR+ breast cancer.
Study NCT06431633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin-based adjuvant chemotherapy~Cisplatin - CAS 15663-27-1, is a platinum coordination complex with potent anti-neoplastic activity. Induces apoptosis in cancer cells, possibly via caspase-3 activation.
Study NCT06431633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Cisplatin-based adjuvant chemotherapy Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin. Route of administration: Intravenous infusion. Guidelines of Carboplatin administration: According to the standard of each center. Other Name: ATC code: L01XA02
Study NCT06267001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab will be administered IV.
Study NCT06267001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered IV.
Study NCT06267001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab will be administered IV.
Study NCT06267001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IV.
Study NCT06445972 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV Infusion
Study NCT06445972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/M\^2 IV infusion
Study NCT06445972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/M\^2 IV infusion
Study NCT06445972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2870
Description: 3 mg/kg or 4 mg/kg IV Infusion
Study NCT05841394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 1
Description: Physiologic saline for injection, 100 ml/bag, q24h, following Ilaprazole Sodium with a time interval of 12 h.
Study NCT05841394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo 2
Description: Physiologic saline for injection, 100 ml/bag, q12h, dosing on the first day.
Study NCT06452277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088
Description: Tablet, oral
Study NCT06452277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion
Study NCT06452277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: IV infusion
Study NCT06452277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT06452277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: IV infusion
Study NCT06561217 — intervention group
Intervention type: OTHER
Intervention: Chart review
Description: Chart review
Study NCT06051383 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self management
Description: patients will be assessed at base line using tool I,II Patients will receive self-management intervention in the form of sessions. Four to six patients in each session. Each session will last approximately 20 minutes~Session 1 :~* Introduction to the concept of self-management.~* Education/reassurance~* Managing fluid intake.~* Caffeine abstinence~* Alcohol advice~Session 2 :~* Adjusting medications~* Constipation advice.~* Strategies for dribbling. pelvic floor exercise.~* Double-voiding.~* Bladder re-training.~Session 3:~• Booster session All sessions are supported with a self-management booklet given in session. All patients will be reassessed after three months
Study NCT05852652 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryolipolysis and aerobic exercise
Description: the patients in this arm adjusted low calorie diet . According to the Recommended Dietary Intake (RDI), the low-calorie diet plan with three carefully calculated meals had a balanced macronutrient quantity of carbohydrate and protein, was low in fat, and was abundant in fruits, vegetables, and dietary fibres.~they got two cryolipolysis sessions,one session in the month ,they got two sessions in two months,then took our outcome measures with walking 60 minutes in the park
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 2.4% Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 2.4% Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with lower nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 5% Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-cigarette with 5% Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with higher nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 3mg Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with lower nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 3mg Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with lower nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 6mg Nicotine with Menthol and Tobacco Flavors
Description: Flavor availability is menthol and tobacco/unflavored with higher nicotine concentration.
Study NCT06077240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Pouches with 6mg Nicotine with Tobacco Flavor Only
Description: Flavor availability is tobacco/unflavored only with higher nicotine concentration.
Study NCT06523608 — intervention group
Intervention type: OTHER
Intervention: Standard survillance protocol
Description: Patients will be followed every 6 months. They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
Study NCT06523608 — intervention group
Intervention type: OTHER
Intervention: Stratified survillance protocol
Description: Based on PLEASE and M10LS20 scores, patients will be followed every 3 or 12 months. Low-risk patients will be followed once per year, and high-risk patients every 3 months.~They will undergo at each visit an ultrasound examination including liver stiffness and a routine blood test, including AFP. Other examinations are carried out according to the standard of medical care. Blood, urine and stool tests as well as instrumental diagnostics such as duplex ultrasound, computer tomography, MR-tomography, endoscopies, bone marrow punctures, elastographies, TIPS implantations, operations, etc. will be performed as part of the usual diagnostic clarification.
Study NCT05260073 — intervention group
Intervention type: DRUG
Intervention: Tirbanibulin
Description: Participants will be treated with tirbanibulin ointment 1% (2.5 mg tirbanibulin in 250 mg) as 1 single-dose packet per application, for 5 consecutive days.
Study NCT04924530 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Co-ingestion of maltodextrin with a high fat meal